Articles tagged with Cancer Cells
Scientists create a molecule that tethers BCL6 to CDK9, switching on apoptosis genes in cancer cells. The approach aims to eliminate cancer cells with high specificity and avoid treatment resistance.
A new gold-based compound has been developed that slows tumour growth in animals by 82%, targeting cancers more selectively than standard chemotherapy drugs. It also blocks cancer cells' ability to form new blood vessels, a promising approach to reducing toxic side effects.
Researchers found that a type of cancer cell death called necroptosis can release a molecule called interleukin-1α, weakening the immune response and allowing tumors to grow faster. By blocking this molecule, cancer treatments like chemotherapy and immunotherapy may become more effective.
Researchers discovered that cancer grows uniformly throughout its mass, with every region equally active and potentially harboring aggressive mutations. This finding challenges the traditional 'two-speed' entity model of tumors, where rapidly dividing cells on the surface and slower activity in the core were thought to exist.
Researchers explore adapting agricultural techniques, such as integrated pest management, to treat cancer. By managing cancer as a chronic condition, adaptive therapy aims to overcome treatment resistance and improve patient outcomes.
Researchers at University of Toronto have developed a new microfluidic platform, ReSCUE, that allows for unprecedented control and manipulation of tumor shapes. This enables the formation, release, and transfer of patient-derived tumoroids, providing insights into how tumor shape predicts cancer cell behavior and aggressiveness.
Researchers explore potential synergies between chemotherapy, cannabinoids, and intermittent serum starvation in treating colorectal cancer. Combining these therapies could create a strong synergy by depriving cancer cells of glucose, making them more susceptible to treatment.
A recent study from Uppsala University found that genetic variation in cancer cells can enhance the effects of an already approved cancer drug, talazoparib, against liver cancer cells lacking a functional CYP2D6 enzyme. This suggests a potential for more individually tailored and effective cancer therapies.
Researchers at Anglia Ruskin University are investigating the complex relationship between fat tissue and colorectal cancer. The study aims to enhance knowledge of the tumour microenvironment, uncover new molecules crucial for cancer growth, and develop more effective treatments.
Researchers developed a new AI-powered diagnostic system, FastGlioma, which reveals invisible cancerous tissue in brain tumor surgery. The technique may delay or prevent recurrence of high-grade tumors and improve patient survival.
Researchers successfully delivered anti-cancer ASO molecules to lung tumor sites using human red blood cells, demonstrating potent anti-cancer effects against NSCLC. The approach utilizes EGFR-targeting moieties to home in on cancerous cells, offering a potentially powerful treatment modality for personalized cancer medicine.
This review explores the anticancer mechanisms of selected medicinal plants, discussing their potential for therapeutic development. The plants exert effects through cell cycle arrest, apoptosis induction, and disruption of signaling cascades, offering promising alternatives to conventional therapies.
Researchers at the University of Pittsburgh found that blocking the uptake of lactic acid, a key factor in T cell exhaustion, can reinvigorate these cells. This new approach shows promise for improving tumor control and treatment outcomes in various cancers.
A new University of Cincinnati Cancer Center study reveals how copper helps clear cell renal cell carcinoma cells grow and advance. Copper accumulation is associated with worse outcomes for patients with ccRCC, and it boosts energy and growth in cancer cells.
Researchers found higher levels of CD47 expression linked to more aggressive tumors, immune cells, and oncogenic signaling. Targeting CD47 could lead to improved outcomes with immunotherapy drugs, especially in cases where existing treatments are ineffective.
A new mechanism has been found by which tumor cells escape the immune system, involving a protein called IRGQ. Studies have shown that suppressing IRGQ can trigger a stronger immune response against cancer cells, leading to improved survival rates in liver cancer patients.
A new study by MUSC researchers reveals how cancer cells develop resistance to hydroxychloroquine, an anti-malarial drug repurposed for cancer therapy. The findings suggest that targeting specific metabolic and export pathways can prevent resistance, opening the door for novel combination therapies.
Researchers have developed a new tool that collects and analyzes extracellular vesicles to detect cancer cells more accurately. The digital approach allows for simultaneous analysis of multiple biomarkers, enabling earlier detection of cancer at curable stages.
A new anti-cancer agent has been developed that targets glutathione in cancer cells, switching it off and causing tumor shrinkage. The catalyst-based therapy accumulates specifically in tumor tissue, showing promising results in animal studies and potential for further human trials.
Researchers discovered that INPP4B drives the movement of lysosomes to the periphery of pancreatic cancer cells, releasing their contents into the extracellular space and disrupting the structural support network. This process enables the cells to migrate and invade other tissues, making it easier for the cancer to spread.
Scientists have identified a molecular mechanism that eliminates defective cells during faulty cell division, shedding new light on the fundamental processes involved. The discovery could lead to more effective treatments for blood cancer by targeting cells with multiple centrosomes, which are a hallmark of disrupted division.
Researchers discovered that tumor dormancy in breast cancer can be triggered by specific signaling changes within small cell clusters, called tumor emboli. Key mechanisms include reduced activity of mTOR and structural shifts in E-cadherin, which are regulated by the PI3K pathway.
Researchers at Tel Aviv University have discovered a new cancer mechanism that prevents the immune system from attacking tumors. The discovery was made by reversing this mechanism, which stimulates the immune system to fight cancer cells, including those resistant to prevailing forms of immunotherapy.
Researchers developed a new imaging analysis technique combining biomarkers and tumor architecture to create a 'fingerprint' for each patient, enabling precise prognosis and treatment response. The method identified two previously undetected groups of patients, with exceptional good or bad prognoses.
Researchers have discovered key mutations in certain cancer cells that render WRN inhibitors ineffective. The study found that prolonged exposure to these inhibitors can lead to the acquisition of mutations in the WRN gene, allowing cancer cells to survive and develop resistance.
Researchers created a 3D-printed model to mimic the conditions that spur cancer cells' spread, allowing them to visualize this process in real-time. The model revealed a mechanism where low oxygen levels promote metastasis through lowering pH levels.
Researchers found that WNTinib significantly delayed tumour growth and extended survival in mice with hepatoblastoma cells harboring CTNNB1 mutations. The treatment also showed promise in shrinking tumors in patients' tumor tissue models, with some tumors disappearing completely.
Researchers at Van Andel Institute discovered that cutting off cancer cells' access to fat makes them highly sensitive to ferroptosis and drugs that induce it. This finding has promising implications for developing new anti-cancer strategies and potentially tailoring diets to enhance treatment effectiveness.
A new study has identified four categories of cancer mutations that cause drug resistance, providing targets for drug development and potential effective second-line therapies. The research highlights DNA changes that could be explored further to treat patients with specific genetic mutations.
A groundbreaking study has demonstrated the clinical success of a new nanoparticle-based, laser-guided therapy for prostate cancer treatment. The therapy successfully eliminated cancerous cells in 73% of patients after 12 months while preserving key functions and side effects.
Researchers have engineered probiotic bacteria to educate the immune system to destroy cancer cells, opening the door for a new class of cancer vaccines. The bacterial vaccine proved more efficacious than peptide-based therapeutic cancer vaccines in studies using mouse models of advanced colorectal and melanoma cancers.
A recent study published in Nature Cancer has discovered that cancer cells exhibit opposing pro and antitumor programs, with the former promoting metastasis and the latter combating tumor growth. This finding opens new avenues for therapeutic strategies to target highly aggressive and therapy-resistant tumors.
Scientists discovered a unique way in which yeast cells adapt to starvation by coating their mitochondria with massive molecular complexes called ribosomes. This adaptation has potential implications for cancer treatment as it may help overcome the challenges faced by cancer cells when they are starved of nutrients.
Researchers at Montefiore Einstein Comprehensive Cancer Center have discovered a natural immune mechanism in mice that stops escaped cancer cells from developing into tumors elsewhere in the body. Alveolar macrophages recognize and interact with disseminated cancer cells, producing signals that keep them dormant.
A new study found that 5-fluorouracil kills cells by interfering with RNA synthesis, not DNA damage. The findings suggest that combining 5-FU with drugs affecting RNA synthesis could make it more effective in patients with gastrointestinal cancers.
Researchers created the largest atlas of how tumor architecture changes in response to immune checkpoint therapy. The study found that multiple T cells recognize different neoantigens, altering the tumor ecosystem, and challenged prevailing theories on immunotherapy.
Researchers at ETH Zurich have found an antidepressant, vortioxetine, effective against glioblastomas, a particularly aggressive brain tumor with no cure. The drug's ability to cross the blood-brain barrier and trigger a signalling cascade makes it promising for treating this deadly tumour.
Researchers at Tel Aviv University discovered that aneuploid cells, which have an abnormal number of chromosomes, are more susceptible to certain types of anticancer drugs. The studies found that disrupting the MAPK pathway increases the sensitivity of these cancer cells to chemotherapy.
The University of Oklahoma Health Sciences has received a $5.3 million National Institutes of Health grant to support advanced cancer research in Oklahoma. The grant will help early-career researchers establish independently funded laboratories and build technology infrastructure specific to cancer investigations.
Researchers discover cancer cells rely on sphingolipids for immune evasion and signaling. The findings suggest targeting lipid production could enhance existing immunotherapies.
Researchers at WVU are working on a project to inhibit the myeloperoxidase enzyme, which feeds pancreatic cancer growth. By targeting this enzyme, they hope to boost the body's immune system to fight cancer, showing promise in mouse models and potential for future clinical trials.
Researchers at Aston University have created a potential treatment for bone cancer using gallium-doped bioactive glasses, which has shown a 99% success rate in killing osteosarcoma cells. The therapy also promotes early stages of bone formation and regenerates diseased bones.
Researchers propose a new approach to understanding cancer evolution, acknowledging the importance of environmental influences and epigenetic changes. By refining the clonal evolution model, they aim to develop more effective cancer therapies that consider the full complexity of cancer cell evolution.
Researchers have designed molecular 'cages' that selectively target and eliminate cancer cells in acidic microenvironments. The study, led by CSIC, proposes a new approach to overcome chemotherapy limitations, with potential for future ionophore development.
A new study from the CUNY Graduate Center uncovers key mechanisms responsible for the transformation of adult progenitor cells into brain tumors. Researchers found that a specific combination of genetic mutations and growth factor overproduction drives this transformation, highlighting the importance of epigenetic changes in glioma dev...
Researchers developed a new tool to track immune health patterns over time, revealing how checkpoint inhibitor therapies work together to recruit new T cells. The study found that the combination therapy produces waves of new T cells with each dose, rather than continually strengthening existing ones.
Researchers have developed a nanodrug that targets miR-10b, a small noncoding RNA implicated in cancer cell invasion and proliferation. The study shows that inhibiting miR-10b reduces the stemness of breast cancer cells, supporting dedifferentiation as a potential therapeutic mechanism.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
The LENN system protects and efficiently releases NA therapies within the cytoplasm of target cells, overcoming low efficiencies and immune system clearance issues. It is biomanufacturable, biodegradable, and highly tunable, targeting a variety of cells depending on their tumor-specific surface markers.
Researchers identified CYP2J2 as a key enzyme in austocystin D-mediated cytotoxicity. Overexpression of CYP2J2 enhanced cytotoxic effects, while depletion reduced sensitivity to austocystin D.
Researchers developed tumor cell-coated carbon nanohorns to deliver paclitaxel to colon cancer, exhibiting high accumulation at tumors and strong chemotherapeutic effects. The treatment also demonstrated a robust photothermal effect and immune responses, effectively destroying tumors.
Researchers have identified HLA-E as a critical negative regulator of NK cell interactions with cancer cells. Disrupting NKG2A:HLA-E interactions may stimulate both NK cell and cytotoxic T cell effector functions against cancer, offering a promising anti-cancer strategy.
A new study published in Nature Medicine shows that precision therapy can improve survival for men with metastatic castration-resistant prostate cancer. The treatment, which involves analyzing the genetic profile of the tumor, has been shown to be more effective than chemotherapy in patients whose tumors have specific mutations.
A new platform called CellTracksColab has been introduced to simplify cell tracking data analysis, enabling researchers to study cell movement and behavior. The tool provides a user-friendly interface for analyzing complex data, leading to new insights into diseases such as cancer metastasis.
Researchers developed a faster and more precise method to separate particles in fluids, enabling quicker sorting of cells in blood samples and removal of pollutants in water. The improved technique uses specially engineered channels and high polymer concentrations to guide particles and increase accuracy.
A research team from the University of Hong Kong has discovered that the protein FANCM promotes resistance to cancer drugs called PARP inhibitors. This discovery could lead to new treatment strategies and broaden the application of PARP inhibitors across various cancer types.
Researchers from the University of Sheffield have developed a new form of immunotherapy using nanoparticles that delays the onset of resistance to hormone therapy in prostate cancer. This innovative approach stimulates immune cells called T cells to attack cancer cells, marking a significant breakthrough in treating prostate cancer.
Researchers have used cryo-electron microscopy to reveal the structural basis of how cells regulate ferritin, a protein that stores iron. This understanding could lead to the development of drugs that block ferritin's interaction with NCOA4, slowing down aggressive cancer cells.
A new study finds that combining an inhibitor of a metabolic pathway with chemotherapy could improve treatment outcomes in triple negative breast cancer brain metastases. Inhibiting fatty acid synthase, an enzyme critical for cancer cell survival, shows promise in improving chemotherapy efficacy.
Cancer cells can attach themselves to liver cells when specific proteins are present, allowing them to colonize and form new tumors. This discovery provides insights into the metastatic process and may lead to potential treatments that prevent cancer from establishing new tumors.